{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:47:22Z","timestamp":1795121242611,"version":"4.10.3"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.diabres.2024.111648","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T01:45:28Z","timestamp":1712022328000},"page":"111648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Epidemiology of NAFLD \u2013 Focus on diabetes"],"prefix":"10.1016","volume":"210","author":[{"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0005","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0016-5085(88)90183-7","article-title":"Alcohol like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury","volume":"95","author":"Diehl","year":"1988","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0010","first-page":"560","article-title":"Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations","volume":"11","author":"Younossi","year":"1998","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.diabres.2024.111648_b0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/01.mcg.0000135372.10846.2a","article-title":"Obesity and non-alcoholic fatty liver disease in chronic hepatitis C","volume":"38","author":"Younossi","year":"2004","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cld.2007.02.002","article-title":"Pathologic assessment of non-alcoholic fatty liver disease","volume":"11","author":"Bondini","year":"2007","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.diabres.2024.111648_b0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.diabres.2024.111648_b0035","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2024.111648_b0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1542-3565(04)00014-X","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"2","author":"Younossi","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.diabres.2024.111648_b0045","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0050","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"Younossi","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.diabres.2024.111648_b0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","article-title":"In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not","volume":"62","author":"Younossi","year":"2013","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.diabres.2024.111648_b0065","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/17474124.2013.811047","article-title":"Interaction of type 2 diabetes and nonalcoholic fatty liver disease","volume":"7","author":"Verderese","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.diabres.2024.111648_b0080","doi-asserted-by":"crossref","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0085","doi-asserted-by":"crossref","first-page":"e000198","DOI":"10.1136\/bmjgast-2018-000198","article-title":"Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"5","author":"Golabi","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0090","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/liv.14038","article-title":"Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States","volume":"39","author":"Golabi","year":"2019","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.diabres.2024.111648_b0095","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","article-title":"Global NASH council. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi","year":"2019","journal-title":"Clin Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12876-019-0972-6","article-title":"Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States","volume":"19","author":"Golabi","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.diabres.2024.111648_b0115","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep4.1419","article-title":"Mortality related to nonalcoholic fatty liver disease is increasing in the United States","volume":"3","author":"Paik","year":"2019","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0120","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.diabres.2024.111648_b0125","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD according to the body composition and presence of metabolic abnormalities","volume":"4","author":"Golabi","year":"2020","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hep4.1841","article-title":"Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD","volume":"6","author":"Vieira Barbosa","year":"2022","journal-title":"Hepatol Commun"},{"issue":"146","key":"10.1016\/j.diabres.2024.111648_b0135","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"26","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2024.111648_b0140","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.diabres.2024.111648_b0145","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.diabres.2024.111648_b0150","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0155","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MCG.0000000000001172","article-title":"Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality","volume":"54","author":"Hester","year":"2020","journal-title":"J Clin Gastroenterol."},{"issue":"3","key":"10.1016\/j.diabres.2024.111648_b0160","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0165","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0170","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"31","key":"10.1016\/j.diabres.2024.111648_b0175","doi-asserted-by":"crossref","first-page":"e11518","DOI":"10.1097\/MD.0000000000011518","article-title":"Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: Data from the scientific registry of transplant recipients (SRTR): 1994 to 2016","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0180","doi-asserted-by":"crossref","first-page":"e004318","DOI":"10.1136\/bmjopen-2013-004318","article-title":"Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study","volume":"4","author":"Younossi","year":"2014","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.diabres.2024.111648_b0185","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep4.1599","article-title":"The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007\u20132017","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol Commun."},{"issue":"9","key":"10.1016\/j.diabres.2024.111648_b0190","article-title":"The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes","volume":"4","author":"Younossi","year":"2022","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.diabres.2024.111648_b0195","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cld.2023.01.007","article-title":"Economic burden and patient-reported outcomes of nonalcoholic fatty liver disease","volume":"27","author":"Stepanova","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0200","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","article-title":"A global survey of physicians knowledge about nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.diabres.2024.111648_b0205","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor Awareness of Liver Disease Among Adults With NAFLD in the United States","volume":"5","author":"Alqahtani","year":"2021","journal-title":"Hepatol Commun."},{"key":"10.1016\/j.diabres.2024.111648_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2023.06.012","article-title":"Identification of High Risk NAFLD Patients in Endocrinology Clinics","author":"Younossi","year":"2023","journal-title":"Endocr Pract."},{"issue":"3","key":"10.1016\/j.diabres.2024.111648_b0215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apt.17346","article-title":"A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis","volume":"57","author":"Younossi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0220","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0225","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0230","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: State of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0235","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.diabres.2024.111648_b0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-021-00565-8","article-title":"Natural history of NAFLD: Knowns and unknowns","volume":"19","author":"Tsochatzis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0245","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11901-017-0378-2","article-title":"Natural history of NAFLD\/NASH","volume":"16","author":"Ekstedt","year":"2017","journal-title":"Curr Hepatol Rep"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.17292","article-title":"Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD","volume":"57","author":"Amangurbanova","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"10290","key":"10.1016\/j.diabres.2024.111648_b0255","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.diabres.2024.111648_b0260","article-title":"Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus","volume":"13","author":"Padda","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.diabres.2024.111648_b0265","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.diabres.2024.111648_b0270","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"Hazlehurst","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2024.111648_b0275","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.20283","article-title":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway","volume":"40","author":"Feldstein","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111648_b0280","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0028-1091981","article-title":"Mechanisms of disease progression in nonalcoholic fatty liver disease","volume":"28","author":"Jou","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.diabres.2024.111648_b0285","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.diabres.2024.111648_b0290","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.diabres.2024.111648_b0295","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms21113863","article-title":"Japan study group of Nafld Jsg-Nafld: The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2024.111648_b0300","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabres.2024.111648_b0305","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.diabres.2024.111648_b0310","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.diabres.2024.111648_b0315","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1464-5491.2005.01582.x","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults","volume":"22","author":"Jimba","year":"2005","journal-title":"Diabetes Med"},{"key":"10.1016\/j.diabres.2024.111648_b0320","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fphar.2019.00877","article-title":"NAFLD and diabetes: Two sides of the same coin? Rationale for gene-based personalized NAFLD treatment","volume":"10","author":"Xia","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2024.111648_b0325","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0330","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.diabres.2024.111648_b0335","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hep Communications"},{"issue":"10397","key":"10.1016\/j.diabres.2024.111648_b0340","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.diabres.2024.111648_b0345","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.4239\/wjd.v12.i9.1479","article-title":"Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?","volume":"12","author":"Khandelwal","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabres.2024.111648_b0350","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between nonalcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.diabres.2024.111648_b0355","article-title":"Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes","volume":"5","author":"Mertens","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.diabres.2024.111648_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109827","article-title":"Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes","volume":"186","author":"de Vries","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2024.111648_b0365","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0370","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.diabres.2024.111648_b0375","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2023","journal-title":"Gut."},{"key":"10.1016\/j.diabres.2024.111648_b0380","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0385","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.diabres.2024.111648_b0390","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/joim.12964","article-title":"Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study","volume":"286","author":"Park","year":"2019","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.diabres.2024.111648_b0395","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13992","article-title":"Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease","volume":"39","author":"Paik","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.diabres.2024.111648_b0400","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2024.111648_b0405","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111648_b0410","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity"},{"issue":"17","key":"10.1016\/j.diabres.2024.111648_b0415","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"NASH clinical research network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.diabres.2024.111648_b0420","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"2","key":"10.1016\/j.diabres.2024.111648_b0425","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2024.111648_b0430","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0435","doi-asserted-by":"crossref","first-page":"e0055","DOI":"10.1097\/HC9.0000000000000055","article-title":"Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the agile 3+ and 4 scores","volume":"7","author":"Noureddin","year":"2023","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.diabres.2024.111648_b0440","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HEP.0000000000000351","article-title":"Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes","volume":"78","author":"Pennisi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.diabres.2024.111648_b0445","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.diabres.2024.111648_b0450","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cmet.2018.07.003","article-title":"Remission of human type 2 diabetes requires decrease in liver and pancreas fatcontent but is dependent upon capacity for b cell recovery","volume":"28","author":"Taylor","year":"2018","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.diabres.2024.111648_b0455","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-8587(19)30076-2","article-title":"Understanding the mechanisms of reversal of type 2 diabetes","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.diabres.2024.111648_b0460","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"532","key":"10.1016\/j.diabres.2024.111648_b0465","article-title":"Blocking TLR4-NF-\u03baB pathway protects mouse islets from the combinatorial impact of high fat and fetuin-A mediated dysfunction and restores ability for insulin secretion","volume":"15","author":"Mukhuty","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"10.1016\/j.diabres.2024.111648_b0470","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724005588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724005588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T06:45:13Z","timestamp":1731393913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724005588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":94,"alternative-id":["S0168822724005588"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111648","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology of NAFLD \u2013 Focus on diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111648"}}